Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci; S. Piaserico; R. B. Warren; A. K. Gupta; W. Cantrell; Z. Draelos; P. Foley; A. Igarashi; R. G. Langley; A. Asahina; M. Young; M. Falqués; I. Pau-Charles; A. M. Mendelsohn; S. J. Rozzo; K. Reich

doi:10.1111/bjd.19866

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci, S. Piaserico, R. B. Warren, A. K. Gupta, W. Cantrell, Z. Draelos, P. Foley, A. Igarashi, R. G. Langley, A. Asahina, M. Young, M. Falqués, I. Pau-Charles, A. M. Mendelsohn, S. J. Rozzo, K. Reich

科研成果: 期刊稿件 › 文章 › 同行评审

64 引用（Scopus）

源语言	英语
页（从-至）	323-334
页数	12
期刊	British Journal of Dermatology
卷	185
期	2
DOI	https://doi.org/10.1111/bjd.19866
出版状态	已出版 - 8月 2021
已对外发布	是

!!!ASJC Scopus Subject Areas

皮肤医学

访问文件

10.1111/bjd.19866

其它文件与链接

引用此

Thaci, D., Piaserico, S., Warren, R. B., Gupta, A. K., Cantrell, W., Draelos, Z., Foley, P., Igarashi, A., Langley, R. G., Asahina, A., Young, M., Falqués, M., Pau-Charles, I., Mendelsohn, A. M., Rozzo, S. J., & Reich, K. (2021). Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 185(2), 323-334. https://doi.org/10.1111/bjd.19866

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. / Thaci, D.; Piaserico, S.; Warren, R. B. 等.
在: British Journal of Dermatology, 卷 185, 号码 2, 08.2021, 页码 323-334.

科研成果: 期刊稿件 › 文章 › 同行评审

Thaci, D, Piaserico, S, Warren, RB, Gupta, AK, Cantrell, W, Draelos, Z, Foley, P, Igarashi, A, Langley, RG, Asahina, A, Young, M, Falqués, M, Pau-Charles, I, Mendelsohn, AM, Rozzo, SJ & Reich, K 2021, 'Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*', British Journal of Dermatology, 卷 185, 号码 2, 页码 323-334. https://doi.org/10.1111/bjd.19866

@article{3bb1e0fde32646cfba59c9ffecc28e8e,

title = "Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*",

author = "D. Thaci and S. Piaserico and Warren, {R. B.} and Gupta, {A. K.} and W. Cantrell and Z. Draelos and P. Foley and A. Igarashi and Langley, {R. G.} and A. Asahina and M. Young and M. Falqu{\'e}s and I. Pau-Charles and Mendelsohn, {A. M.} and Rozzo, {S. J.} and K. Reich",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2021",

month = aug,

doi = "10.1111/bjd.19866",

language = "English",

volume = "185",

pages = "323--334",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28

T2 - pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

AU - Thaci, D.

AU - Piaserico, S.

AU - Warren, R. B.

AU - Gupta, A. K.

AU - Cantrell, W.

AU - Draelos, Z.

AU - Foley, P.

AU - Igarashi, A.

AU - Langley, R. G.

AU - Asahina, A.

AU - Young, M.

AU - Falqués, M.

AU - Pau-Charles, I.

AU - Mendelsohn, A. M.

AU - Rozzo, S. J.

AU - Reich, K.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85105583577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105583577&partnerID=8YFLogxK

U2 - 10.1111/bjd.19866

DO - 10.1111/bjd.19866

M3 - Article

C2 - 33544883

AN - SCOPUS:85105583577

SN - 0007-0963

VL - 185

SP - 323

EP - 334

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此